Chimeric Therapeutics Recruits First Patient in Cell Therapy Cancer Trial; Shares Rally 16%

MT Newswires Live07-22

Chimeric Therapeutics Recruits First Patient in Cell Therapy Cancer Trial; Shares Rally 16% Chimeric Therapeutics (ASX:CHM) recruited the first patient for its phase one/two trial for the cell therapy...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2453784020?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-07-22 11:36","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2453784020","market":"fut","top_or_hot":-1,"title":"Chimeric Therapeutics Recruits First Patient in Cell Therapy Cancer Trial; Shares Rally 16%","media":"MT Newswires Live","content":"<div>\n<p>Chimeric Therapeutics Recruits First Patient in Cell Therapy Cancer Trial; Shares Rally 16% Chimeric Therapeutics (ASX:CHM) recruited the first patient for its phase one/two trial for the cell therapy...</p>\n\n<a href=\"https://www.mtnewswires.com/\">Source Link</a>\n\n</div>\n","source":"mtnewswires_live","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Chimeric Therapeutics Recruits First Patient in Cell Therapy Cancer Trial; Shares Rally 16%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nChimeric Therapeutics Recruits First Patient in Cell Therapy Cancer Trial; Shares Rally 16%\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-07-22 11:36 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.mtnewswires.com/><strong>MT Newswires Live</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Chimeric Therapeutics Recruits First Patient in Cell Therapy Cancer Trial; Shares Rally 16% Chimeric Therapeutics (ASX:CHM) recruited the first patient for its phase one/two trial for the cell therapy...</p>\n\n<a href=\"https://www.mtnewswires.com/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CHM.AU","symbol_name":"CHIMERIC THERAPEUTICS LTD","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2453784020","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2453784020","pubTimestamp":1721619393,"sourceInfo":{"source_id":"mtnewswires_live","name":"MT Newswires Live"},"weMediaInfo":null,"summary":"Chimeric Therapeutics Recruits First Patient in Cell Therapy Cancer Trial; Shares Rally 16% Chimeric","collect":0,"end_time":0,"defaultTopTitle":"mtnewswires.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"CHM.AU":"CHIMERIC THERAPEUTICS LTD","XJO.AU":"标普/澳交所 200指数","XKO.AU":"标普/澳交所 300指数","LENZ":"Therapeutics","BK4139":"生物科技","BK7067":"生物科技","XAO.AU":"标普/澳交所 普通股指数"},"translate_title":"Chimeric Therapeutics在细胞治疗癌症试验中招募了第一名患者；股价上涨16%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CHM.AU":1,"LENZ":1,"XAO.AU":1,"XJO.AU":1,"XKO.AU":1},"content_text":"Chimeric Therapeutics Recruits First Patient in Cell Therapy Cancer Trial; Shares Rally 16% Chimeric Therapeutics (ASX:CHM) recruited the first patient for its phase one/two trial for the cell therapy CDH17, according to a Monday filing with the Australian bourse.The trial aims to investigate the safety, response rate, and optimal dose of the cell therapy CDH17 in patients with colorectal and gastric cancers, as well as intestinal tumors, the cell therapy firm said in the filing.Shares of Chimeric Therapeutics rallied 16% in recent trade.","kind":null,"is_publish_news":false,"is_publish_highlight":false,"is_publish_live":true,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2453784020"}